BTK and head and neck cancer: Since treatment with AVL-292 led to an increase in E-Cadherin expression and, at the same time, to a reduction in Slug protein levels, BTK inhibition may represent a powerful tool to interfere with the EMT and metastatic phenotype of HNSCC, thus improving the OS and DFS of head and neck cancer patients.